-
Due to the long half-lives of nevirapine and efavirenz, it is now recommended that when non-nucleoside reverse transcriptase inhibitor (nnRTI)-containing antiretroviral regimens are discontinued, backbone nucleoside analogs should be continued for 4-7 days to reduce the likelihood of development of nnRTI resistance.
-
In October 2005, the American Committee on Immunization Practices provided provisional recommendations for the acellular pertussis vaccine (Tdap) (ADACELTM, Sanofi Pasteur) as a single booster dose for persons 11-64 years of age.
-
The STAR Trial (Tamoxifen and Raloxifene); FDA Actions
-
The CDC identified 17 patients with community-acquired pneumonia (CAP) due to S. aureus by following up on reports from the Emerging Infections Network of the Infectious Disease Society of America (IDSA) during the 2003-2004 influenza season.
-
While the use of anti-tnf agents for the treatment of diseases such as rheumatoid arthritis (RA) is known to be associated with an increased risk of serious infections and malignancies, the degree of risk has remained undefined.
-
-
Pulmonary embolism occurs commonly in patients with unexplained exacerbations of chronic obstructive pulmonary disease.
-
All of the currently available non-invasive techniques for carotid artery imaging give accurate results when there is a high-grade stenosis (70-99%), but contrast-enhanced MRA is slightly more sensitive.
-
The FDA has approved a new agent for smoking cessation. Varenicline blocks the action of nicotine but provides a lower level of stimulation of dopamine release to reduce craving and withdrawal symptoms.
-
The TNT study (Treat to New Targets) demonstrated that intensive lipid lowering (ILL) with atorvastatin 80 mg/d in patients with stable coronary artery disease (CAD) provided more benefit than simply achieving an LDL of 100 mg/dL with atorvastatin 10 mg/d.
